Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II–III locally advanced breast cancer

References

• Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.
   PubMed Web of Science ®Google Scholar
• Hortobágyi GN, Buzdar A. Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs. 1993;45(2):10–9.
   PubMedGoogle Scholar
• Lowenthal EA, Carpenter JT. The use of anthracyclines in the adjuvant treatment of breast cancer. J Cancer Treat Rev. 1995;21(3):199–214.
   PubMed Web of Science ®Google Scholar
• Gabizon AA, Patil Y, La-Beck NM. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Updat. 2016;29:90–106. Nov
   PubMed Web of Science ®Google Scholar
• Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, et al. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1991;12(9):2148–52.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. JCO. 2012;30(15):1796–804.
   PubMedGoogle Scholar
• Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer. J Clin Breast Cancer Clin Breast Cancer 2003;4:S26–S33.
   PubMedGoogle Scholar
• Gradishar V. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005;365(9472):1687–717.
   PubMed Web of Science ®Google Scholar
• Tuxen MK, Cold S, Tange UB, Balslev E, Nielsen DL. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide +/- trastuzumab followed by docetaxel in locally advanced breast cancer. Acta Oncol. 2014;53(10):1440–5. Oct
   PubMed Web of Science ®Google Scholar
• O’Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–9. Mar
   PubMed Web of Science ®Google Scholar
• David R. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer. J Anti-Cancer Drugs. 2008;7(19):733–7
   Google Scholar
• Grazia A. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer. J Anticancer Res. 2010;9(30):3817–21.
   Google Scholar
• Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, et al. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015;151(3):597–606. Jun
   PubMed Web of Science ®Google Scholar
• Tampaki EC, Tampakis A, Alifieris CE, Krikelis D, Pazaiti A, Kontos M, et al. Efficacy and safety of neoadjuvant treatment with bevacizumab, liposomal doxorubicin, cyclophosphamide and paclitaxel combination in locally/regionally advanced, HER2-negative, grade III at premenopausal status breast cancer: a phase II study. Clin Drug Investig. 2018;38(7):639–48. Jul
   PubMed Web of Science ®Google Scholar
• Berruti A, Amoroso V, Gallo F, Bertaglia V, Simoncini E, Pedersini R, et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. JCO. 2014;32(34):3883–91. 1
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet. 2014;384(9938):164–72.
   PubMed Web of Science ®Google Scholar
• Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. 2012;1(1):10.
   PubMedGoogle Scholar
• Ansari L, Shiehzadeh F, Taherzadeh Z, Nikoofal-Sahlabadi S, Momtazi-Borojeni AA, Sahebkar A, et al. The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials. Cancer Gene Ther. 2017;24(5):189–93.
   PubMed Web of Science ®Google Scholar
• Gogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountzilas G, Tsavdaridis D, et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic cooperative oncology group. Ann Oncol. 2002;13(11):1737–42. Nov
   PubMed Web of Science ®Google Scholar
• Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, et al. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer. 2010;17(4):298–302.
   PubMed Web of Science ®Google Scholar
• Mao Z, Shen K, Zhu L, Xu M, Yu F, Xue D, et al. Comparisons of cardiotoxicity and efficacy of anthracycline-based therapies in breast cancer: a network meta-analysis of randomized clinical trials. Oncol Res Treat. 2019;42(7/8):405–9.
   PubMed Web of Science ®Google Scholar
• Rau K-M, Lin Y-C, Chen Y-Y, Chen J-S, Lee K-D, Wang C-H, et al. Pegylated liposomal doxorubicin (Lipo-Dox(R)) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study. BMC Cancer. 2015;15(1):423.
   PubMedGoogle Scholar
• Liesse K, Harris J, Chan M, Schmidt ML, Chiu B. Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumor patients: a systematic review. Journal of Pediatric Hematology/Oncology. 2018;40(6):417–25.
   PubMed Web of Science ®Google Scholar
• Reichardt P, Tabone M-D, Mora J, Morland B, Jones RL. Risk–benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. 2018;14(25):2663–76.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155–66.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. JCO. 2009;27(1):127–45.
   PubMed Web of Science ®Google Scholar